Polyclonal Immunoglobulin E specific to Theobroma cacao proteins (Anti-cocoa IgE)

Polyclonal Immunoglobulin E (IgE) antibodies specific to Theobroma cacao proteins are the primary immunological mediators responsible for Type I hypersensitivity reactions to cocoa and chocolate products (Source: StatPearls, IgE Mediated Hypersensitivity). These antibodies are produced by B cells following sensitization to specific cocoa allergens, most notably the 7S globulin known as The c 1 and the albumin-like protein The c 2 (Source: WHO/IUIS Allergen Nomenclature). These IgE molecules circulate in the blood and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to cocoa proteins, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes (Source: PubMed, PMID: 24388012). This physiological response results in clinical symptoms ranging from mild urticaria and oral allergy syndrome to life-threatening anaphylaxis. Therapeutic strategies targeting these antibodies include the use of anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE to prevent mast cell sensitization (Source: PubChem, CID: 16130347), and allergen-specific immunotherapy (AIT) designed to induce immune tolerance and shift the antibody profile toward protective IgG4 (Source: PubMed, PMID: 30102047).

Other names

Cocoa-specific IgEChocolate-specific IgEAnti-Theobroma cacao IgEAnti-The c 1 IgEAnti-The c 2 IgE

Neutralization of circulating IgE and prevention of its binding to high-affinity FcεRI receptors on mast cells and basophils, thereby inhibiting the allergic cascade (Source: FDA, Xolair Prescribing Information).